Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -35,6 +35,9 @@
35	35	In January 2018, Torrent also acquired Bio-Pharm, Inc. (BPI) a generic pharmaceuticals and OTC Company, based in Levittown Pennsylvania, USA, which also included a US FDA registered manufacturing facility.
36	36
37	37
	38	+[[image:TORNTPHARM1.jpg]]
	39	+
	40	+
38	38	== Torrent Group ==
39	39
40	40	The Torrent Group, founded by Late Mr. U. N. Mehta in 1959 and currently lead by Mr. Sudhir Mehta and Mr. Samir Mehta, is a driving force dedicated to transforming life.{{footnote}}https://torrentpharma.com/index.php/site/info/aboutgroup{{/footnote}}
...	...	@@ -95,25 +95,24 @@
95	95	|(% style="width:264px" %)Levittown Pennsylvania|(% style="width:162px" %)19,020 sq mtrs.|(% style="width:251px" %)120 Mn
96	96
97	97
98		-<img>
	101	+[[image:TORNTPHARM2.png]]
99	99
100	100
101		-Research & Development
	104	+== Research & Development ==
102	102
103	103
104		-The company's state-of-the art R & D Centre at Bhat near Ahmedabad has one of the most advanced infrastructures for both basic and applied research. Spread over a lush green campus and housed in an architecturally unique energy efficient structure, the R & D Centre is spread out over 125,000 Sq. mts. with a built-up area of 41,000 Sq. mts. It is managed by a dedicated staff, who work round the clock to take care of all its needs. It houses 999 inquisitive minds whose passion is to discover and develop medicines to help patients lead a longer and healthier life.
	107	+The company's state-of-the art R & D Centre at Bhat near Ahmedabad has one of the most advanced infrastructures for both basic and applied research. Spread over a lush green campus and housed in an architecturally unique energy efficient structure, the R & D Centre is spread out over 125,000 Sq. mts. with a built-up area of 41,000 Sq. mts. It is managed by a dedicated staff, who work round the clock to take care of all its needs. It houses 999 inquisitive minds whose passion is to discover and develop medicines to help patients lead a longer and healthier life.{{footnote}}https://torrentpharma.com/index.php/site/info/rnd{{/footnote}}
105	105
106		-[[https:~~/~~/torrentpharma.com/index.php/site/info/rnd>>url:https://torrentpharma.com/index.php/site/info/rnd]]
107	107
	110	+=== Discovery Research ===
108	108
109		-Discovery Research
110		-
111	111	The Company is currently developing several in-house New Chemical entities (NCE) in the areas of metabolic, cardiovascular, gastrointestinal, dermatological and respiratory disorders. The Company has cumulatively filed 818 patent applications for NCEs from these and earlier projects in all major markets of which, 497 patents were granted so far.
112	112
113	113	The most advanced discovery programme of the Company is a metabolic modulator NCE, 'omzotirome', for the treatment of diabetes. This program me is currently undergoing the pivotal phase-3 clinical trial in key markets where the Company has presence, with India gearing up to be the first to launch. The Company believes that this asset is uniquely positioned to address the consequences of Cardiometabolic-Based Chronic Disease (CMBCD), which is assuming alarming proportions in India and other emerging economies besides developed countries.
114	114
115		-NDDS
116	116
	117	+=== NDDS ===
	118	+
117	117	Novel Drug Delivery Systems (NDDS) emerged from application of new technology platforms to design products with an aim to reposition existing drugs, if required through an alternate route of administration. The aim is to improve their performance with respect to efficacy, safety and patient compliance through enhanced bio-availability, dosage reduction, frequency and onset of action.
118	118
119	119	The Company’s pipeline includes several NDDS programmes, adapted for existing medications, which will give the Company an edge over its competitors through differentiation. The Company is currently focusing its R&D efforts on several innovative projects in the area of complex generics, with respect to oral solids, foams/ointments/creams and nasal delivery.
...	...	@@ -121,10 +121,9 @@
121	121	Foam-based topical product for psoriasis was launched successfully. Another product for the indication of acute pain management through nasal route of delivery was also launched. Nasal route of delivery is also being explored for management of vitamin B12 deficiency. The phase-3 trial has been completed and filed for marketing approval.
122	122
123	123
	126	+[[image:TORNTPHARM4.jpg]]
124	124
125		-<img pipline>
126	126
127		-
128	128	Business Overview
129	129
130	130	Torrent Pharma blazed a new trail in the Indian Pharmaceuticals industry by successfully implementing the concept of niche marketing. Torrent Pharmaceuticals was the pioneers in initiating the concept of niche marketing and today, is ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments.